Bausch Health Exploring Potential Divestiture Of Eye Care Units: Bloomberg

Bausch Health Exploring Potential Divestiture Of Eye Care Units: Bloomberg

Bausch Health Companies Inc (NYSE: BHC) said in August that it would spin off its eye-care unit and operate it as an independent, publicly traded company. As a standalone company, Bausch + Lomb could be valued at $20 billion to $30 billion, according to Bloomberg Intelligence.

The business has attracted interest from private equity bidders as well as strategic buyers.

The unit includes eye-health products like contact lenses and surgical devices. Its Bausch + Lomb segment raked $1.24 billion in the fourth quarter.